Virtual Histology:From Theory to Vulnerable Plaque Detection Shaoliang Chen MD Nanjing First Hospital Nanjing Cardiovascular Hospital.

Slides:



Advertisements
Similar presentations
Remodelage et plaque dathérome: intérêt des IEC à forte dose G. Derumeaux Lyon Conflit d'intérêt : Servier, Actelion, Sanofi-Aventis.
Advertisements

Implications from PROSPECT and Future Directions Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Providing.
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
IVUS-VH & Vulnerable Plaque Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon City, S. Korea Jang-Ho Bae, MD., PhD. Heart Center.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
COI Disclosure I have no conflict of interest to disclose I have no conflict of interest to disclose.
PBL CV 2 Pathophysiology of coronary artery disease.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Can IVUS Define Plaque Features that Impact Patient Care? A Pichard L Satler, K Kent, R Waksman, W Suddath, N Bernardo, N Weissman, M Angelo, D Harrington,
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Qu Xinkai Shanghai Chest Hospital Shanghai Jiaotong University Value of comprehensive cardiac evaluation using MSCT in patients with CTO.
Navigating the Coronary Circulation: Angiography vs IVUS Pearls and Pitfalls Philippe L. L’Allier, MD Montreal Heart Institute Tuesday, March 27, 2007.
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
When I Use IVUS Neal Uren MD FRCP Consultant Cardiologist Royal Infirmary Edinburgh.
The Pathology of Cardiac Interventions Dr Stephen Preston Royal Bournemouth Hospital Dr Patrick J Gallagher University of Southampton.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
STATINS PRE-PCI: A Prospective, Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef VESELKA CardioVascular Center.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
OCT Assessment of Late Stent Malapposition after DES
Ravi Doobay and Dr. Eric Harrison We care about the health of our firefighters Tampa Fire Rescue: Saving our Firefighters from Heart Disease.
Fu Wai Hospital Jie Qian
Progression, Regression, and Remodeling of Atherosclerosis ( 동맥경화증의 진행, 퇴축, 그리고 재성형 ) Hyo-Soo Kim, MD, PhD Cardiovascular Center, Seoul National University.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
New techniques for the “invasive diagnosis” of the vulnerable plaque Antwerp, 17 March 2006.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Saqib Chowdhary Wythenshawe Hospital STENT THROMBOSIS How Do IVUS & OCT Help.
CARDIAC CT IN SCREENING FOR CAD Hossein Nademi MD CARDIOLOGIST JAVADOL-A-EME HEART HOSPITAL OCT
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
IVUS in Peripheral Procedures
R4 하 상 진. Introduction Circulation May 1;115(17):
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Are the Culprit Lesions Severely Stenotic? J Am Coll.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
It’s Both the Vulnerable Patient and the Vulnerable Plaque
Atherosclerosis and HDL Therapy New Virtual Histology Findings
IVUS, FFR, OCT- Which Should I Use For PCI?
Use of OCT to Localize Macrophages
OCT and Stent Thrombosis
CTA Characterization of Vulnerable Plaque Minneapolis Heart Institute
The Role of Inflammation and Immune Responses
Cardiovascular Research Technologies
Near-Infrared Spectroscopy: Lipid-Rich Plaque Study Update
Should we Use OCT in STEMI Patients?
Solved & Unsolved Issues
Clinical need for determination of vulnerable plaques
Near Infrared Spectroscopy: Case Studies and Clinical Relevance
When IVUS? When FFR? Assessing Intermediate Lesions
BVS Expand: First Results of Wide Clinical Applications
Advanced carotid plaque characterization: Assessment of vulnerability
MACE Trial Rationale, Study Design, and Current Status
On behalf of J. Belardi, M. Leon, L. Mauri,
Circ Cardiovasc Imaging
מדידת רמת האנזים Lp-PLA2 בדם כסמן עצמאי למידת הסיכון להתקפי לב ואירועים מוחיים. סמן בלתי תלוי הנוסף לגורמי הסיכון המוכרים פרופ' נתן בורנשטיין מנהל יח'
Apoprotein B, Small-Dense LDL and Impaired HDL Remodeling Is Associated With Larger Plaque Burden and More Noncalcified Plaque as Assessed by Coronary.
Circ Cardiovasc Interv
William Insull, MD  The American Journal of Medicine 
3-Year Clinical Outcomes From the RESOLUTE US Study
Chapter 12 Pathophysiology of Atherosclerosis
Volume 383, Issue 9918, Pages (February 2014)
Section 4: Plaque dynamics and stenosis
Bioresorbable Vascular Scaffolds in Cardiac Allograft Vasculopathy: A New Therapeutic Option  Flavio Ribichini, MD, Michele Pighi, MD, Giuseppe Faggian,
Histological evaluation disqualifies IMT and calcification scores as surrogates for grading coronary and aortic atherosclerosis  Armelle Meershoek, Rogier.
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment William Insull, Jr, MD Professor of Medicine and Pediatrics,
Presentation transcript:

Virtual Histology:From Theory to Vulnerable Plaque Detection Shaoliang Chen MD Nanjing First Hospital Nanjing Cardiovascular Hospital

Acute coronary syndrome (ACS) commonly results from rupture of thin-cap fibroatheroma (TCFA), and occasionally results from erosion or calcified nodules. Pathological features of TCFA are the presence of thin fibrous cap (<65μm) and a large lipid core. Bruke AP et al. N Eng J Med.1997;336: Falk E, et al. Circulation. 1995; 92: Virmani R, et al. Arterioscler Thromb Vasc Biol. 2000; 20: 1262

IVUS – Listening through walls Lumen Lipid Vessel US signal Backscattered signal or RF data Backscattered

From Conventional IVUS imaging to Radiofrequency Signal Processing Conventional IVUS images are derived from the envelope of the RadioFrequency signal recorded by the US transducer Conventional IVUS images are derived from the envelope of the RadioFrequency signal recorded by the US transducer More information can be derived from the processing of the raw RF signal itself for: More information can be derived from the processing of the raw RF signal itself for:  tissue characterization  evaluation of mechanical properties  assessment of flow blood wall catheter

Virtual histology IVUS (VH-IVUS) uses amplitude and frequency of echoes Especially, Necrotic Core component is known to related to plaque vulnerability. VH- IVUS differentiates coronary plaque into 4 types Frequency Amplitude

“Conventional” IVUS Assessment of Patients Presenting with ACS

Echolucent Plaque=Vulnerable Plaque?

Echolucent Plaque and VH

Echolucent Plaque and VH(n=53) VH Phenotype of Echolucent Lesion Echolucent Zone Adjacend of Echolucent Zone Yang AHA 2008

Plaque Classification 1. “ Adaptive Intimal Thickening ” Plaque comprised of nearly all fibrous tissue (<5% of fibrofatty, calcification and/or NC plaque). 2. Pathological Intimal Thickening” – Mainly mixture of fibrous, fibrofatty (>5%), and necrotic core and some calcified tissue <5%.

Plaque Classification “Fibro-Atheroma” – Fibrotic cap and significant Necrotic Core (confluent NC >5% of total plaque volume) in fibrotic and/or fibrofatty tissue It will very likely be that the most important goal is to differentiate the FibroAtheroma plaque types from the other three plaque types during assessments of high risk lesions for rupture.

Definition of thin-cap fibroatheroma (TCFA) by VH-IVUS In at least 3 consecutive frames, (1)Percent Necrotic Core area to plaque area> 10% without evident overlying fibrous component (2)Percent plaque area to vessel area > 40% Rodriguez-Granillo et al. J Am Coll Cardiol,2005; 46:

Not only volume of NC, but also extent of NC contact with lumen are important. Measurement of angle of NC contact with lumen (NCCL) was performed by a MATLABTM at Thoraxcenter, Erasmus MC, by Dr. Garcia-Garcia HM. Overall NC 31.1% Blue area; major NCCL, 28.3% purple plus blue area Total NCCL, 30.5% Red line; angle of the major NCCL, 9° White and red line; angle of the total NCCL, 35° Sawada T, Shite J et al Eur Heart J 2008; 29:

By necrotic core angle contact with lumen, VH-IVUS may estimate thin fibrous cap. However, IVUS can not visualize surface fibrous cap due to limited resolution >100μm.

Thin-Cap FibroAtheroma (TCFA) Courtesy of Renu Virmani

VH is entirely dependent on drawing accurate borders

Is VH-TCFA really vulnerable?

Recent MI Culprit lesion Distal Prox

Acute Plaque Rupture 79 years old male Unstable, DM (type II), hypertension, lipid disorder, prior MI VH IVUS; TCFA with three layers

52-yo Male with Abn Nuc Scan (DB)

Pre-intervention Post-intervention (Peak CK-MB release measured 21.2 ng/ml)

Global VH-IVUS Registry

Serial VH Evaluation

Case Examples Baseline TCFA PIT Follow-up ThCFAFibroticTCFA

Changes of plaque morphology TCFA n=20 ThCFA n=93 PIT n=62 65% 10% 25% 90% 3%1% 6% 71% 10% Fibrotic/fibrocalcific plaques did not change. Kubo T, JACC in press

Changes at MLA site Plaque Area Lumen Area

Serial VH in Patients After Stenting: DES vs BMS Kubo ACC2008

Serial VH of DES BaselineFollow-up Stented segment Reference segment

Serial VH of BMS Baseline Follow-up Stented segment Reference segment

Abutting Necrotic Core to the Lumen * p<0.05 Kubo ACC2008

The PROSPECT Trial 700 pts with ACS UA (with ECGΔ) or NSTEMI or STEMI >24 o 1-2 vessel CAD undergoing PCI at up to 40 sites in U.S., Europe PCI of culprit lesion(s) Successful and uncomplicated Metabolic S. Waist circum Fast lipids Fast glu HgbA1C Fast insulin Creatinine Biomarkers Hs CRP IL-6 sCD40L MPO TNFα MMP9 Lp-PLA2 others Formally enrolled PI: Gregg W. Stone Sponsor: Abbott Vascular; Partner: Volcano

3-vessel imaging post PCI Culprit artery, followed by non-culprit arteries

PROSPECT Methodology IVUS/VH Core Lab Analysis Lesions are classified into 5 main sub-types based on VH composition

PROSPECT: Acute MI

MLA: 6.1 mm 2

PROSPECT: Baseline Features N = 697

PROSPECT: Imaging Summary Length of coronary arteries analyzed

PROSPECT: Imaging Summary Non culprit angio and IVUS lesions (LM, P/MLAD, PLCX and P/M/DRCA only)

PROSPECT: Imaging Summary Non culprit angio and IVUS lesions (LM, P/MLAD, PLCX and P/M/DRCA only)

PROSPECT: Imaging Summary Per pt incidence of IVUS lesions with MLA <4.0 mm 2

PROSPECT: Imaging Summary Presence of ≥1 VH lesion subtypes (2765 lesions in 614 pts)

PROSPECT: Imaging Summary Per patient incidence of VH-TCFAs

Longitudinal sections from 50 autopsy pts 10.9 meters examined from 148 coronary arteries 44% of pts had ≥1 TCFA (range 0 - 6) Mean 0.46 TCFAs/pt (0.55 vs in pts dying of CV ds. vs. other) /pt in hearts with ruptured plaques - Cheruvu PK et al. JACC 2007;50:940–9